Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38results about How to "Bioadhesive" patented technology

Polygonatum odoratum buccal tablet and production method thereof

The invention provides a polygonatum odoratum buccal tablet and a production method thereof. The polygonatum odoratum buccal tablet comprises the following components in parts by weight: 8-15% of polygonatum ordoratum submicron powder, 30-40% of mannitol, 33-45% of microcrystalline cellulose, 2-6% of xylitol, 1-2% of ethyl alcohol, 0.1-0.3% of menthol, 3-5% calcium sulfate and 0.1-0.3% chitosan, wherein the granularity of the polygonatum ordoratum submicron powder is 1600-1700 meshes. The production method comprises the following steps: preparing a filler, manufacturing a soft material, prilling, gathering granules, tabletting, sterilizing, and packing and the like. According to the invention, the polygonatum ordoratum can exist in the form of submicron powder, so that the fragrance and taste of the polygonatum ordoratum can be retained to the greatest extent, the effective constituent of the polygonatum ordoratum can be better absorbed inside an oral cavity, and the health care effect of products can be greatly enhanced. The polygonatum ordoratum bucaal tablet has the characteristics of being good in taste, smooth in surface, conform in color and luster, good in hardness, better in disintegrative characteristic and applicable to being taken by the middle-aged and aged people, and people with diseases of hyperlipidemia, hyperglycemia and obesity.
Owner:李嘉

Cationic adhesion type mycophenolate mofetil nano eye drop

InactiveCN101590015AImprove solubilityIncreased corneal resorption featuresOrganic active ingredientsSenses disorderSolubilityPhospholipid
The invention relates to a cationic adhesion type mycophenolate mofetil nano eye drop, which comprises mycophenolate mofetil of which the mass percentage concentration is 1 percent, proper amount of osmotic pressure modifying agent and pH modifying agent. The eye drop is characterized in that the eye drop also comprises chitosan, Pluronic F-68 and phospholipid, wherein the mass percentage concentration of the phospholipids in the eye drop is between 0.2 and 2 percent; the mass percentage concentration of the Pluronic F-68 in the eye drop is between 0.5 and 4 percent; the mass percentage concentration of the chitosan in the eye drop is between 0.5 and 4 percent; the molecular weight of the chitosan is between 5,000 and 300,000; the deacetylation degree is more than 85 percent; and the grain diameter of the mycophenolate mofetil is between 10 and 700 nm. The eye drop has the characteristics that: the mycophenolate mofetil with nanometer grain diameter improves the medicament solubility, the safety and the effectiveness; mycophenolate mofetil medicament particles are charged with positive charges so as to be favorable for improving the cornea absorption of the medicament, improving the medicament effect, prolonging the medicament duration, and greatly improving the cornea adhesion.
Owner:SHANDONG EYE INST

Composite denitrification biological tank

The invention discloses a composite denitrification biological tank which comprises a biological tank body, and the biological tank body is composed of a water distribution system, a gas backwashing system, a biological filler, a filler support, a backwashing wastewater drainage channel, a backwashing wastewater drainage pipe and a carbon source accurate adding control system. The water distribution system comprises a water inlet pipe, water distribution pipes, a water outlet pipe and a water outlet channel, the water inlet pipe communicated with the biological tank body is installed on one end face of the bottom of the biological tank body, the water distribution pipes are evenly arranged on the water inlet pipe located in the biological tank body at equal intervals, and a water outlet channel is arranged on the upper portion of the biological tank body. The water outlet pipe is mounted at the side end of the upper part of the biological tank body, is distributed away from one side of the water inlet pipe and can realize fluid communication with the water outlet channel; and the air backwashing system comprises a backwashing air pipe and an air inlet control valve, and the backwashing air pipe is mounted on one side, deviating from the water inlet pipe, of the biological tank body. Thecomposite denitrification biological tank has the advantages of high efficiency, stability, simplicity in management, low cost and low energy consumption.
Owner:北京弘昇达环境科技有限公司

Calcium alginate composite microspheres for stabilizing water-in-oil type Pickering emulsion and preparation method thereof

The invention discloses calcium alginate composite microspheres for stabilizing water-in-oil type Pickering emulsions and a preparation method thereof, belonging to the technical field of material polymers. Alkylsilane-grafted inorganic nanoparticles are coated on the surface of calcium alginate microspheres to form calcium alginate composite microspheres. The particle size distribution of the microspheres is 2-8 μm; it has a core-shell structure, the core is hollow, and the shell has two layers. The total thickness of the two-layer shell is 1~1.5µm, calcium alginate is the inner shell, and inorganic nanoparticles are assembled to form the outermost shell; it overcomes the fact that chitosan coated on the surface of calcium alginate microspheres can only stabilize the oil-in-water type Pickering emulsion, as a drug carrier, can only encapsulate oil-soluble drugs but not water-soluble drugs. The use of improved emulsion polymerization to prepare calcium alginate composite microspheres also has the biocompatibility of calcium alginate, Adhesion and encapsulation of protein macromolecules can stabilize the water-in-oil Pickering emulsion very well. It can widely expand the application of Pickering emulsion as a drug carrier in the fields of biomedicine, cosmetics industry, food industry and enzyme engineering.
Owner:SOUTHWEST JIAOTONG UNIV

Cerebral aneurysm micro-occlusion device

The invention discloses a cerebral aneurysm micro-occlusion device. The cerebral aneurysm micro-occlusion device comprises a main occlusion device body, a filling liquid, a conveying pipe and a pushing catheter, wherein the main occlusion device body comprises a check valve; a liquid inlet end of the check valve sleeves a limit block; a liquid outlet end of the check valve sleeves a fluid blockingbody; the fluid blocking body comprises a biological gel material with elastic deformation performance; the filling liquid enters the fluid blocking body through the pushing catheter and the check valve. The components of the device have small dependence on the process size and are particularly applicable to micro cerebral aneurysms. The filling liquid enters the fluid blocking body through the pushing catheter and the check valve, so that the biological gel material with the elastic deformation performance is elastically deformed under the filling action of the filling liquid, and correspondingly the biological gel material expands and plays a role in blocking a cerebral aneurysm. The biological gel material is selected for making the fluid blocking material, has biological adhesion andcan successfully adhere to the cerebral aneurysm, so that the strength of the cerebral aneurysm is enhanced, and the rupture risk of the cerebral aneurysm is reduced.
Owner:WUHAN VICKOR MEDICAL TECH CO LTD

Cationic adhesion type mycophenolate mofetil nano eye drop

InactiveCN101590015BImprove solubilityIncreased corneal resorption featuresOrganic active ingredientsSenses disorderSolubilityPhospholipid
The invention relates to a cationic adhesion type mycophenolate mofetil nano eye drop, which comprises mycophenolate mofetil of which the mass percentage concentration is 1 percent, proper amount of osmotic pressure modifying agent and pH modifying agent. The eye drop is characterized in that the eye drop also comprises chitosan, Pluronic F-68 and phospholipid, wherein the mass percentage concentration of the phospholipids in the eye drop is between 0.2 and 2 percent; the mass percentage concentration of the Pluronic F-68 in the eye drop is between 0.5 and 4 percent; the mass percentage concentration of the chitosan in the eye drop is between 0.5 and 4 percent; the molecular weight of the chitosan is between 5,000 and 300,000; the deacetylation degree is more than 85 percent; and the grain diameter of the mycophenolate mofetil is between 10 and 700 nm. The eye drop has the characteristics that: the mycophenolate mofetil with nanometer grain diameter improves the medicament solubility,the safety and the effectiveness; mycophenolate mofetil medicament particles are charged with positive charges so as to be favorable for improving the cornea absorption of the medicament, improving the medicament effect, prolonging the medicament duration, and greatly improving the cornea adhesion.
Owner:SHANDONG EYE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products